Gilead Sciences
latest news & developments
180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough
The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics.…
What will HIV funding look like in 2026?
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in
SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses?
The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October
Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year
SA plans anti-HIV jab roll-out at hundreds of clinics by April
The health department hopes to make the twice-a-year anti-HIV injection lenacapavir available soon and to be buying generics by 2027
SA gets R520 million to buy the twice-a-year anti-HIV jab – but there’s a snag
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it has already been awarded and was cut by 16% in June